Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for cardioprotection in acute aluminum phosphide poisoning
PACTR201911790018554Phase 4Completed
- Sponsor
- fatma gaber sobeeh
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of melatonin in Aluminium phosphide poisoning (2 arms), sponsored by fatma gaber sobeeh. Primary endpoints: Troponin I level, Arterial blood gases and 2 more. Started Apr 2019; status: completed.
02
Drugs
melatonin
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on PACTR201911790018554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201911790018554.